Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDA OTCMKTS:ENZN NASDAQ:LIFE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$0.96+4.7%$1.15$0.84▼$2.45$10.37M0.56360,299 shs65,223 shsENZNEnzon Pharmaceuticals$5.75$6.04$1.50▼$12.99$4.27M-0.031,234 shs143 shsLIFEEthos Technologies Inc. Class A Common Stock$17.70-14.5%$0.00$9.45▼$32.50$1.11BN/A541,080 shs564,895 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia+4.75%-5.45%-20.42%-15.49%-49.20%ENZNEnzon Pharmaceuticals0.00%-1.29%+0.88%-11.81%-31.14%LIFEEthos Technologies Inc. Class A Common Stock-14.53%-18.47%+9.87%+1,769,999,900.00%+1,769,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$0.96+4.7%$1.15$0.84▼$2.45$10.37M0.56360,299 shs65,223 shsENZNEnzon Pharmaceuticals$5.75$6.04$1.50▼$12.99$4.27M-0.031,234 shs143 shsLIFEEthos Technologies Inc. Class A Common Stock$17.70-14.5%$0.00$9.45▼$32.50$1.11BN/A541,080 shs564,895 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia+4.75%-5.45%-20.42%-15.49%-49.20%ENZNEnzon Pharmaceuticals0.00%-1.29%+0.88%-11.81%-31.14%LIFEEthos Technologies Inc. Class A Common Stock-14.53%-18.47%+9.87%+1,769,999,900.00%+1,769,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 2.00Hold$25.002,517.80% UpsideENZNEnzon Pharmaceuticals 0.00N/AN/AN/ALIFEEthos Technologies Inc. Class A Common Stock 2.67Moderate Buy$27.0052.54% UpsideCurrent Analyst Ratings BreakdownLatest LIFE, ENZN, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026LIFEEthos Technologies Inc. Class A Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/8/2026LIFEEthos Technologies Inc. Class A Common Stock BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $27.005/7/2026LIFEEthos Technologies Inc. Class A Common Stock Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$21.00 ➝ $27.004/22/2026LIFEEthos Technologies Inc. Class A Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold (C-)4/20/2026BCDABioCardia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$60K181.13N/AN/A($0.09) per share-10.61ENZNEnzon Pharmaceuticals$30K141.83N/AN/A$256.94 per share0.02LIFEEthos Technologies Inc. Class A Common Stock$485.82M2.30N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$8.23M-$0.91N/AN/AN/AN/A-5,456.14%-232.75%8/10/2026 (Estimated)ENZNEnzon Pharmaceuticals-$3.41M-$6.84N/AN/AN/AN/A-21.54%-7.22%N/ALIFEEthos Technologies Inc. Class A Common StockN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest LIFE, ENZN, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BCDABioCardia-$0.17-$0.21-$0.04-$0.21N/AN/A5/4/2026Q1 2026ENZNEnzon PharmaceuticalsN/A-$0.84N/A-$0.84N/A$86.54 million3/24/2026Q4 2025BCDABioCardia-$0.20-$0.06+$0.14-$0.06$0.03 millionN/A3/17/2026Q4 2025LIFEEthos Technologies Inc. Class A Common StockN/A$0.42N/A$0.42N/A$110.08 million3/2/2026Q4 2025ENZNEnzon PharmaceuticalsN/A-$2.00N/A-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/ALIFEEthos Technologies Inc. Class A Common StockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.411.12ENZNEnzon Pharmaceuticals0.422.011.16LIFEEthos Technologies Inc. Class A Common StockN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%ENZNEnzon PharmaceuticalsN/ALIFEEthos Technologies Inc. Class A Common Stock61.72%Insider OwnershipCompanyInsider OwnershipBCDABioCardia17.40%ENZNEnzon Pharmaceuticals0.40%LIFEEthos Technologies Inc. Class A Common Stock3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia4011.38 million9.40 millionOptionableENZNEnzon PharmaceuticalsN/A740,000739,000Not OptionableLIFEEthos Technologies Inc. Class A Common Stock61462.99 millionN/AN/ALIFE, ENZN, and BCDA HeadlinesRecent News About These CompaniesEthos Partners with Baseball Legend David Ortiz to Champion Life Insurance as a Family Financial EssentialMay 21 at 9:07 AM | globenewswire.comLingke Wang Sells 46,349 Shares of Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) StockMay 21 at 5:01 AM | americanbankingnews.comChristopher Capozzi Sells 80,586 Shares of Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) StockMay 21 at 5:01 AM | americanbankingnews.comPeter George Colis Sells 60,035 Shares of Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) StockMay 21 at 5:01 AM | americanbankingnews.comEthos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CAO Sells $128,455.38 in StockMay 20 at 6:34 AM | insidertrades.comPyroGenesis Announces $3.0 Million Bought Deal LIFE Offering and Concurrent CEO Private Placement of up to $2.0 MillionMay 19, 2026 | newsfilecorp.comNStandard Uranium Announces Closing of LIFE OfferingMay 19, 2026 | newsfilecorp.comNEthos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Major Shareholder 2019 Gp L.L.C. Gv Sells 60,077 Shares of StockMay 19, 2026 | americanbankingnews.comEthos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Major Shareholder 2019 Gp L.L.C. Gv Sells 87,475 SharesMay 19, 2026 | americanbankingnews.comInsider Selling: Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Major Shareholder Sells 60,077 Shares of StockMay 19, 2026 | insidertrades.comEthos to Present at Upcoming Investor ConferencesMay 15, 2026 | globenewswire.comEthos Announces Early Lock-Up ReleaseMay 13, 2026 | globenewswire.comCopper One Resources Corp. Announces Non-Brokered LIFE Offering of up to $2,500,000May 12, 2026 | thenewswire.comTCRITICAL INFRASTRUCTURE TECHNOLOGIES: $3.0 Million Brokered LIFE Offering Led by Centurion One CapitalMay 12, 2026 | thenewswire.comTStandard Uranium Announces LIFE OfferingMay 11, 2026 | newsfilecorp.comNEthos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Stock Rating Lowered by Wall Street ZenMay 9, 2026 | marketbeat.comBarclays Forecasts Strong Price Appreciation for Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) StockMay 8, 2026 | marketbeat.comEthos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Sets New 1-Year High Following Analyst UpgradeMay 8, 2026 | marketbeat.comEthos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Releases Earnings Results, Misses Expectations By $0.04 EPSMay 7, 2026 | marketbeat.comCitizens Jmp Forecasts Strong Price Appreciation for Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) StockMay 7, 2026 | marketbeat.comEthos Technologies Inc. Class A Common Stock Q1 Earnings Call HighlightsMay 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Bed Bath & Back to Life? An Aggressive Turnaround Takes ShapeBy Jeffrey Neal Johnson | May 1, 2026LIFE, ENZN, and BCDA Company DescriptionsBioCardia NASDAQ:BCDA$0.96 +0.04 (+4.75%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.97 +0.01 (+1.15%) As of 05/22/2026 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Enzon Pharmaceuticals OTCMKTS:ENZN$5.75 0.00 (0.00%) As of 05/22/2026 11:51 AM EasternEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Ethos Technologies Inc. Class A Common Stock NASDAQ:LIFE$17.70 -3.01 (-14.53%) As of 05/22/2026 04:00 PM EasternEthos Technologies Inc operates a technology-driven, direct-to-consumer platform for the distribution of life insurance products. Through its digital underwriting, data analytics, and proprietary technology, it enables consumers to explore, compare, and purchase life insurance policies online. The platform serves consumers, agents, and insurance carriers, and supports the application and policy issuance process through an online interface. The company works with insurance carriers to offer life insurance products in the United States through digital channels and independent agents. It generates revenue through commissions paid by carriers from policies activated and sold through its platform as well as from the provision of third-party administrator services for such policies. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
